K
Kevin J. Horgan
Researcher at Merck & Co.
Publications - 50
Citations - 11456
Kevin J. Horgan is an academic researcher from Merck & Co.. The author has contributed to research in topics: Aprepitant & NK1 receptor antagonist. The author has an hindex of 33, co-authored 50 publications receiving 11211 citations. Previous affiliations of Kevin J. Horgan include National Institutes of Health & Columbia University.
Papers
More filters
Journal ArticleDOI
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Robert S. Bresalier,Robert S. Sandler,Hui Quan,James A. Bolognese,Bettina Oxenius,Kevin J. Horgan,Christopher Lines,Robert H. Riddell,Dion Morton,Angel Lanas,Marvin A. Konstam,John A. Baron +11 more
TL;DR: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Journal Article
The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.
TL;DR: The present data demonstrate that LFA-1/ICAM-1 interaction is a potent costimulus for TCR-mediated activation; this observation, interpreted in light of previous reports, suggests that L FA-1 /ICam-1 is of major physiologic importance as a costimulatory signal.
Journal ArticleDOI
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
Paul J. Hesketh,Steven M. Grunberg,Richard J. Gralla,D. G. Warr,Fausto Roila,Ronald de Wit,Sant P. Chawla,Alexandra D. Carides,Juliana Ianus,M. Elmer,Judith K. Evans,Klaus Beck,Scott A. Reines,Kevin J. Horgan +13 more
TL;DR: Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
Journal ArticleDOI
Regulated expression and binding of three VLA (β1) integrin receptors on T cells
TL;DR: The regulated binding of resting CD4+ human T cells to ECM through three VLA integrins is described, including a novel pathway of VLA-6 binding to laminin (LN).
Journal ArticleDOI
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Sergio Poli‐Bigelli,Jose Rodrigues‐Pereira,Alexandra D. Carides,Guoguang Julie Ma,Krista Eldridge,Anita Hipple,Judith K. Evans,Kevin J. Horgan,Francesca Lawson +8 more
TL;DR: The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial.